Overview

From the Thymus — The Immune System's Headquarters

The thymus gland is where T-cells mature and are educated to distinguish self from non-self. Thymosin Alpha-1 (TA-1) is a peptide derived from thymosin fraction 5 — the thymic extract identified in the 1960s as responsible for T-cell maturation activity. TA-1 was isolated, sequenced, and synthesized by Allan Goldstein's group at the National Cancer Institute in the 1970s.

Under the commercial name Thymalfasin, it has been approved in over 35 countries — most extensively in Asia and parts of Europe — for chronic hepatitis B, hepatitis C (as an adjunct to interferon), and as immunostimulatory support in cancer patients undergoing chemotherapy or radiation. The FDA has not approved it, but it has been studied in multiple US Phase I/II trials.

The thymus involutes (shrinks) with age — TA-1's ability to restore some of that immune function makes it particularly relevant in the longevity and immunosenescence research space. Interest grew significantly after Chinese clinical studies during COVID-19 showed TA-1 administration was associated with reduced mortality in severe cases.

Approved in 35+ Countries as Thymalfasin

Research Areas

What TA-1 Is Studied For

🦠

Antiviral Support

TA-1 activates TLR7, TLR8, and TLR9 — pattern recognition receptors that detect viral RNA/DNA. This activation triggers the innate immune response and increases interferon production, improving the ability to mount an early antiviral defense.

🧬

T-Cell Maturation

TA-1 stimulates the maturation and differentiation of immature T-cells. In immunocompromised individuals, this can restore T-helper cell (CD4+) and cytotoxic T-cell (CD8+) populations toward more functional levels.

🔫

NK Cell Activation

Natural killer cells are the innate immune system's front-line defense against virally infected and tumor cells. TA-1 enhances NK cell cytotoxic activity and is studied in oncology contexts for this reason.

🏥

Oncology Support

As an adjunct in cancer patients, TA-1 is used to support immune function during chemotherapy and radiation — which suppress T-cell populations. Multiple trials have studied it in non-small cell lung cancer and hepatocellular carcinoma.

🧓

Immunosenescence

Age-related decline in immune function (immunosenescence) tracks closely with thymic involution. TA-1 is studied as a potential way to restore some of the immune surveillance activity lost with aging.

🦠

Hepatitis B / C

The primary approved indication across 35+ countries. In HBV: TA-1 combined with antiviral therapy improves viral clearance rates. In HCV (pre-DAA era): TA-1 + interferon showed improved sustained virologic response over interferon alone.

Protocol

Dosing Reference

The internationally approved dose for hepatitis B is 1.6mg SC twice weekly for 6 months. This is the best-validated dosing reference available and is the standard used in most research protocols.

Protocol	Dose	Frequency	Duration
Standard (approved dose)	1.6mg SC	2x per week	3–6 months
Immune support (general)	1.6mg SC	1–2x per week	4–12 weeks
Oncology adjunct	1.6mg SC	2x per week	Per protocol / physician directed

Research Context

Key Data Points

35+

Countries Approved

Thymalfasin (synthetic TA-1) has regulatory approval in Asia, Latin America, and parts of Europe for chronic hepatitis B, hepatitis C, melanoma, hepatocellular carcinoma, and DiGeorge anomaly — a breadth of approved indications rare for any peptide compound.

TLR-2/9

Innate Immune Activation

TA-1 functions as a TLR-2 and TLR-9 agonist — activating pattern recognition receptors that detect bacterial cell wall components and unmethylated CpG DNA (viral/bacterial signatures). This positions it uniquely at the interface of innate and adaptive immunity.

COVID-19 Mortality Reduction

A clinical study found TA-1 treatment was associated with a 9.0% lower mortality rate versus control in sepsis patients with COVID-19 — driving renewed international research interest and expansion of TA-1 into critical care contexts. (Reported in World Journal of Virology, 2020)

1.6mg

Validated Clinical Dose

The internationally approved dose is 1.6mg SC twice weekly. Multiple-dose protocols have been studied up to 16mg over 5–7 days in acute immune contexts. Single-dose research spans 0.8–6.4mg. The standard twice-weekly protocol is the best-validated reference point.

Stacking

Stack Guidance

TA-1 is frequently used as a standalone immune protocol. It pairs well with peptides that support general wellness without overlapping immune mechanisms:

BPC-157 — Gut integrity / general healing NAD+ — Cellular energy and sirtuin support Epitalon — Longevity / pineal support Selank — Immune-adjacent anxiolytic

FAQ

Common Questions

Is TA-1 an immunostimulant or immunomodulator? +

Both, depending on context. In immunocompromised states (cancer, viral infection, aging), TA-1 stimulates toward a more robust immune response. In some autoimmune models, it appears to modulate (not simply amplify) the response — upregulating regulatory T-cells alongside effector cells. This bidirectional property is why it is called an immunomodulator rather than a pure immunostimulant — though in most research contexts, the dominant effect is activation and enhancement of innate and adaptive immune function.

What is the difference between TA-1 and TB-500? +

Completely different mechanisms and purposes. TA-1 (Thymosin Alpha-1) is a thymic immunomodulatory peptide — its effects are entirely in the immune system. TB-500 (Thymosin Beta-4 fragment) promotes tissue repair, angiogenesis, and actin dynamics — it has nothing to do with immune activation. The "thymosin" in the name is a historical artifact of both being derived from thymic extracts in early research; the similarity ends there.

How long until immune effects are noticeable? +

Immune changes are not subjectively obvious the way tissue repair or appetite effects are. In clinical trials, measurable T-cell and NK cell changes are observed within weeks. Antiviral and hepatitis outcomes in trials were measured over 3–6 months. Subjective reports from researchers using TA-1 for general immune support often note reduced frequency and severity of minor infections over a sustained protocol — not an acute response.

What specific diseases is Thymalfasin approved for globally? +

Across its 35+ country approval landscape, Thymalfasin (synthetic TA-1) has been approved for: chronic hepatitis B, hepatitis C (as an adjunct to interferon), hepatocellular carcinoma (liver cancer), melanoma, and DiGeorge anomaly (a congenital immune deficiency). The breadth of oncology approvals reflects TA-1's utility as an immune adjunct when the immune system is suppressed by disease or treatment. These are prescription indications in the countries where they apply — not approved in the United States, where TA-1 is research-stage.

What did the COVID-19 research show? +

During the COVID-19 pandemic, several Chinese hospital systems used TA-1 as an adjunct in severe COVID-19 and sepsis cases. Published data from these clinical applications reported a 9.0% lower mortality rate in patients receiving TA-1 versus control groups in sepsis contexts. This isn't a randomized controlled trial — it's clinical outcome data from emergency use — but it was compelling enough to generate formal research interest in TA-1 for critical illness and sepsis. The mechanism proposed is TA-1's ability to restore T-cell function in the cytokine storm / lymphopenia context that characterizes severe COVID-19.

Is TA-1 safe? What side effects should I expect? +

TA-1 is described in the literature as "usually well tolerated," with injection site reactions (local irritation, redness, or discomfort) being the most commonly reported side effect. Decades of clinical use in 35+ countries with approved status provides a substantially longer safety record than most research-stage peptides. Serious adverse events have not been a prominent feature of the clinical trial record. That said, physician supervision remains appropriate — immune activation has implications for individuals with autoimmune conditions or who are on immunosuppressive medications.

Research Use Only. Thymosin Alpha-1 is approved as Thymalfasin in certain countries for specific indications but is not FDA-approved in the United States. This page provides educational information — not medical advice. Research use only.

Age Verification Required

Thymosin Alpha-1 (TA-1)